Cromatina / Epigenética
Los inhibidores de cromatina/epigenética son compuestos que modulan la estructura y función de la cromatina o interfieren con modificaciones epigenéticas, como la metilación del ADN y la modificación de histonas. Estos inhibidores son herramientas esenciales para estudiar la regulación de la expresión génica y el papel de la epigenética en enfermedades como el cáncer, los trastornos neurológicos y las anomalías del desarrollo. Al dirigirse a los procesos epigenéticos, estos inhibidores pueden alterar los patrones de expresión génica y ofrecer nuevas vías terapéuticas. En CymitQuimica, ofrecemos una amplia selección de inhibidores de cromatina/epigenética de alta calidad para apoyar su investigación en biología molecular, genética y epigenética.
Subcategorías de "Cromatina / Epigenética"
Se han encontrado 2238 productos de "Cromatina / Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MARK-IN-2
CAS:<p>MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor,(IC50:5 nM).</p>Fórmula:C18H18ClF2N5OSPureza:98%Forma y color:SolidPeso molecular:425.88JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44EZH2-IN-14
CAS:<p>EZH2-IN-14 selectively inhibits EZH2 at 12 nM IC50, has >200-fold specificity over EZH1, reducing H3K27me3 levels.</p>Fórmula:C31H39N7O2Forma y color:SolidPeso molecular:541.69TC-A 2317 hydrochloride
CAS:<p>TC-A 2317 HCl inhibits Aurora A kinase (Ki 1.2 nM) over Aurora B (Ki 101 nM), displaying antitumor effects.</p>Fórmula:C19H29ClN6OPureza:98%Forma y color:SolidPeso molecular:392.93Nesuparib
CAS:<p>Nesuparib, a potent PARP/TNKS1 inhibitor, has antitumor properties and potential for treating various diseases.</p>Fórmula:C23H24N6OPureza:99.71%Forma y color:SolidPeso molecular:400.48HL23
CAS:<p>HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC).</p>Fórmula:C44H44N2O7Pureza:98%Forma y color:SolidPeso molecular:712.83BRD4 Inhibitor-23
CAS:<p>BRD4 Inhibitor-23: potent, oral, IC50: BRD4 BD-1 6.21 nM, BD-2 1.44 nM. See WO2022033542A1 Example 1.</p>Fórmula:C22H19F2N3O4SForma y color:SolidPeso molecular:459.47HIF-2α-IN-6
CAS:<p>HIF-2α-IN-6 (117) is a HIF-2α inhibitor [1].</p>Fórmula:C15H13F4NO3SForma y color:SolidPeso molecular:363.33TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Fórmula:C27H25F3N4O4Pureza:99.39% - ≥98%Forma y color:SolidPeso molecular:526.51TC-AC28
CAS:<p>TC-AC28 is a novel potent and selective Brd2(2) ligand.</p>Fórmula:C23H21N5O3Pureza:98%Forma y color:SolidPeso molecular:415.44AMPK-IN-1
CAS:<p>AMPK-IN-1 is an activator of the AMP-activated protein kinase (AMPK) enzyme, specifically targeting the α2β2γ1 isoform with an EC50 of 551 nM.</p>Fórmula:C24H18ClN3O3Forma y color:SolidPeso molecular:431.87GSK4028
CAS:<p>GSK4028 is the enantiomeric negative control of GSK4027, a PCAF/GCN5 bromodomain chemical probe, with a pIC50 of 4.9 in a TR-FRET assay.</p>Fórmula:C17H21BrN4OForma y color:SolidPeso molecular:377.28EPZ011989 HCl(1598383-40-4 Free base)
CAS:<p>EPZ011989 is a highly potent and selective oral EZH2 inhibitor with Ki value <3 nM.</p>Fórmula:C35H51N5O4·HClForma y color:SolidPeso molecular:642.27TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74CBP/p300-IN-19
CAS:<p>CBP/p300-IN-19 inhibits p300/CBP HAT (IC50: 1.4μM), less effective on PCAF/Myst3, shows anti-tumor properties.</p>Fórmula:C30H27N3O3Forma y color:SolidPeso molecular:477.55Gö 7874
CAS:<p>Gö 7874 is a potent, reversible, ATP-competitive, and selective inhibitor of protein kinase C (IC50 = 4 nM for rat brain PKC).</p>Fórmula:C27H26N4O4Forma y color:SolidPeso molecular:470.52HSP70/SIRT2-IN-2
CAS:<p>HSP70/SIRT2-IN-2 (Compounds 1a), a dual inhibitor of SIRT2 and HSP70, exhibits an IC50 of 45.1±5.0 μM against SIRT2 and demonstrates antitumor activity [1].</p>Fórmula:C17H13N3S3Pureza:98%Forma y color:SolidPeso molecular:355.5GSK761
<p>GSK761 inhibits SP140 (IC50: 77.79 nM), hinders monocyte-to-macrophage differentiation, and prompts CD206+ regulatory macrophages.</p>Fórmula:C40H46N4O4Forma y color:SolidPeso molecular:646.82CBB1007 hydrochloride
CAS:<p>CBB1007 Hcl inhibits LSD1 selectively (IC50=5.27μM), blocks H3K4 demethylation, activates genes; less effect on other cells/tissues.</p>Fórmula:C27H39Cl5N8O4Forma y color:SoildPeso molecular:716.91LY3295668
CAS:<p>LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.</p>Fórmula:C24H26ClF2N5O2Pureza:99.68%Forma y color:SolidPeso molecular:489.95HIF-2α agonist 2
CAS:HIF-2α agonist 2 is an HIF-2α agonist with an EC50 value of 1.68 μM for HIF-2α.Fórmula:C13H8Br2N2O2SPureza:98.87%Forma y color:SoildPeso molecular:416.09CCT129202
CAS:<p>CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively.</p>Fórmula:C23H25ClN8OSPureza:98.14%Forma y color:SolidPeso molecular:497.02E7016
CAS:<p>E7016 (GPI 21016) is an orally available PARP inhibitor. E7016 inhibits of DNA repair. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo.</p>Fórmula:C20H19N3O3Pureza:99.02%Forma y color:SolidPeso molecular:349.38FHT-1015
CAS:<p>FHT-1205 is a potent inhibitor (IC50 ≤ 10 nM) of SMARCA4/SMARCA2 ATPase (BRG1 and BRM).</p>Fórmula:C25H25N5O4S3Pureza:98.57%Forma y color:SolidPeso molecular:555.69hRIO2 kinase ligand-1
CAS:<p>hRIO2 kinase ligand-1 is a potent ligand for hRIO2 kinase (Kd: 520 nM).</p>Fórmula:C17H14N2OPureza:99.89%Forma y color:SolidPeso molecular:262.31NPAS3-IN-1
CAS:<p>NPAS3-IN-1 is an NPAS3-ARNT heterodimerization inhibitor that regulates NPAS3 transcription by modulating the heterodimerization of NPAS3 with ARNT.</p>Fórmula:C10H5N3O2S3Pureza:99.56%Forma y color:SolidPeso molecular:295.36AU-15330
CAS:<p>AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells. Cost-effective and quality-assured.</p>Fórmula:C39H49N9O5SPureza:98.21% - 99.62%Forma y color:SolidPeso molecular:755.93PARP-1-IN-4
CAS:<p>PARP-1-IN-4 is a potent PARP-1 inhibitor with potential see anti-tumor activity, and inhibition of PARP-1 may be used in cancer development.</p>Fórmula:C22H15Cl2N3O2Pureza:99.82%Forma y color:SolidPeso molecular:424.28EPZ031686
CAS:<p>EPZ031686 is an effective inhibitor of SMYD3 inhibitor with an IC50 of 3 nM and can be used in studies about cancer.</p>Fórmula:C26H34ClF3N4O4SPureza:99.67%Forma y color:SolidPeso molecular:591.09KDM4-IN-4
CAS:<p>KDM4-IN-4 is a KDM4 inhibitor with anticancer activity that inhibits the KDM4A-Tudor structural domain for cancer research.</p>Fórmula:C16H23NOPureza:99.61%Forma y color:SolidPeso molecular:245.36CPI-0610 carboxylic acid
CAS:<p>CPI-0610 carboxylic acid is a selective BET protein inhibitor with potential anticancer effects.</p>Fórmula:C20H15ClN2O3Pureza:98.62%Forma y color:SolidPeso molecular:366.8HS94
CAS:<p>HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.</p>Fórmula:C15H15N5O2SPureza:95.04%Forma y color:SolidPeso molecular:329.38GNE-375
CAS:<p>GNE-375 is a selective and potent BRD9 inhibitor (IC50: 5 nM).GNE-375 inhibits BRD4, TAF1, and CECR2, and can be used to study epigenetic resistance.</p>Fórmula:C25H29N3O5Pureza:98.99%Forma y color:SolidPeso molecular:451.51JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Fórmula:C18H20N4O3Pureza:98.04% - 98.19%Forma y color:SolidPeso molecular:340.38CeMMEC1
CAS:<p>CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM).</p>Fórmula:C19H16N2O4Pureza:98.9% - 99.92%Forma y color:SolidPeso molecular:336.34Y06137
CAS:<p>Y06137, selective BET inhibitor, Kd 81 nM for BRD4(1), researched for castration-resistant prostate cancer treatment.</p>Fórmula:C27H32N4O2Pureza:99.85%Forma y color:SolidPeso molecular:444.57MC2652
<p>MC2652, a potent LSD1 inhibitor, suppresses leukemia (MV4-11, NB4) and impedes prostate cancer (LNCaP) cell growth.</p>Fórmula:C22H20N2OForma y color:SolidPeso molecular:328.41KDOAM-25 citrate
CAS:<p>KDOAM-25 citrate inhibits KDM5A/B/C/D (IC50: 71, 19, 69, 69 nM); boosts H3K4 methylation, hinders MM1S cell growth. [1]</p>Fórmula:C21H33N5O9Pureza:98%Forma y color:SolidPeso molecular:499.51HDAC6-IN-13
<p>HDAC6-IN-13: potent, selective HDAC6 inhibitor; oral; IC50=0.019μM; targets HDAC1/2/3; crosses blood-brain barrier; anti-inflammatory.</p>Fórmula:C23H22N4OForma y color:SolidPeso molecular:370.45BSI-401
CAS:<p>BSI-401 is an oral inhibitor of PARP-1. It can inhibit pancreatic cancer either when used alone or in synergy with Oxaliplatin.</p>Fórmula:C9H4INO4Forma y color:SolidPeso molecular:317.037HDAC-IN-27
<p>HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).</p>Fórmula:C20H22N4O2Forma y color:SolidPeso molecular:350.416K465
CAS:<p>6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.</p>Fórmula:C26H33ClFN9OPureza:99.78%Forma y color:SolidPeso molecular:542.05Balomenib
CAS:<p>Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.</p>Fórmula:C33H34F3N7O2Forma y color:SolidPeso molecular:617.664O6BTG-C8-αGlu
CAS:<p>O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, it fully inhibits MGMT in HeLaS3 cells and demonstrates no cytotoxicity even at prolonged high doses (up to 20 μM). This compound is suitable for research on MGMT-related cancers.</p>Fórmula:C24H34BrN5O7SForma y color:SolidPeso molecular:616.525DS-9300
CAS:<p>DS-9300, an orally administered potent and selective inhibitor of EP300/CBP HAT, exhibits a significant inhibitory activity with an IC50 value of 28 nM.</p>Fórmula:C25H26F3N5O3Forma y color:SolidPeso molecular:501.50PAD2-IN-1 hydrochloride
<p>PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.</p>Fórmula:C25H30ClFN6O3Forma y color:SolidPeso molecular:517MS8815
CAS:<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Fórmula:C65H87N9O8SForma y color:SolidPeso molecular:1154.51WIZ degrader 8
CAS:<p>WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.</p>Fórmula:C21H27N3O4Forma y color:SolidPeso molecular:385.457MAT2A-IN-19
CAS:<p>MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.</p>Fórmula:C23H15F5N6O3Forma y color:SolidPeso molecular:518.396JPHM-2-167
CAS:<p>PHM-2-167 (Compound 11) is a selective inhibitor of the prolyl hydroxylase domain enzyme (PHD). It inhibits PHD2 and PHD3 with IC50 values of 0.253 μM and 3.95 μM, respectively. PHM-2-167 is applicable for research in chronic kidney disease.</p>Fórmula:C30H28N6O2Forma y color:SolidPeso molecular:504.582
